| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1025384575 |
| P356 | DOI | 10.2165/11585230-000000000-00000 |
| P698 | PubMed publication ID | 21142258 |
| P2093 | author name string | Michael K Racke | |
| Daniel P Ankeny | |||
| Aaron Boster | |||
| P2860 | cites work | BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 |
| Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system | Q28144436 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| A study of oligoclonal band negative multiple sclerosis. | Q29544969 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis | Q29620481 | ||
| B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice | Q30490538 | ||
| A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. | Q33882987 | ||
| Surprising pleiotropy of nerve growth factor in the treatment of experimental autoimmune encephalomyelitis | Q33919193 | ||
| Mechanism of action of mitoxantrone | Q33984097 | ||
| Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. | Q34052870 | ||
| B cells and antibodies in CNS demyelinating disease | Q34100103 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis | Q34201336 | ||
| Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination | Q34279716 | ||
| Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice | Q34411828 | ||
| B-cell targeting in rheumatoid arthritis and other autoimmune diseases | Q34514813 | ||
| Insights into the immunopathogenesis of multiple sclerosis | Q34546121 | ||
| Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response | Q35087990 | ||
| Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. | Q35769109 | ||
| Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein | Q35818687 | ||
| Role of C5a in inflammatory responses | Q36072464 | ||
| Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis | Q36159214 | ||
| Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis | Q36232675 | ||
| Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? | Q36277898 | ||
| Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors | Q36349536 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| Immunogold localization and analysis of IgG during immune-mediated demyelination | Q36437522 | ||
| B-cells in multiple sclerosis. | Q36652323 | ||
| Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries | Q36825327 | ||
| Can the immune system be harnessed to repair the CNS? | Q37168160 | ||
| Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury | Q37233232 | ||
| Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. | Q37285430 | ||
| Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy | Q37368148 | ||
| Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). | Q37381231 | ||
| Immunoglobulin-containing cells in multiple-sclerosis plaques | Q39450637 | ||
| Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis | Q40141450 | ||
| Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy | Q40353603 | ||
| Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. | Q40385043 | ||
| BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors | Q40419059 | ||
| Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. | Q40960823 | ||
| B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice | Q41028078 | ||
| Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies | Q41573607 | ||
| Cerebrospinal fluid markers in multiple sclerosis: an overview | Q41734482 | ||
| B cells and autoantibodies: complex roles in CNS injury | Q42164770 | ||
| Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? | Q42943930 | ||
| Treatment of IgM antibody associated polyneuropathies using rituximab | Q43069450 | ||
| Mechanisms of action of glatiramer acetate in multiple sclerosis | Q43565879 | ||
| NGF rescues human B lymphocytes from anti-IgM induced apoptosis by activation of PKCzeta | Q43831594 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. | Q44903307 | ||
| Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients | Q45192232 | ||
| Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein | Q45763195 | ||
| Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis | Q46266579 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| An open label study of the effects of rituximab in neuromyelitis optica | Q46482210 | ||
| Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis | Q47969566 | ||
| A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases | Q47978322 | ||
| Intrathecal activation of the complement system and disability in multiple sclerosis | Q47995950 | ||
| Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation | Q48138942 | ||
| Determinants of Human B Cell Migration Across Brain Endothelial Cells | Q48328973 | ||
| B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization | Q48364459 | ||
| Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
| Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis | Q48949365 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta. | Q51648083 | ||
| Think membranes and ion channels. | Q51897188 | ||
| Nerve growth factor is an autocrine survival factor for memory B lymphocytes. | Q52048078 | ||
| Relapsing and remitting experimental autoimmune encephalomyelitis in B cell deficient mice. | Q52539853 | ||
| Immune surveillance in multiple sclerosis patients treated with natalizumab. | Q54606407 | ||
| Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus | Q56903374 | ||
| Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus | Q59031797 | ||
| Intrathecal IgM synthesis in neurologic diseases: Relationship with disability in MS | Q60390376 | ||
| Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis | Q67465393 | ||
| Immunoglobulins promote remyelination in the central nervous system | Q68705712 | ||
| A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease | Q68834759 | ||
| Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis | Q71147380 | ||
| High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice | Q71641038 | ||
| Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells | Q71744340 | ||
| Systemic humoral factors participating in the course of spinal cord injury | Q72718767 | ||
| Immunomodulatory effects of interferon beta-1a in multiple sclerosis | Q73276261 | ||
| Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis | Q73822066 | ||
| TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS | Q74419758 | ||
| Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein | Q74456215 | ||
| Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury | Q74582496 | ||
| B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo | Q77404703 | ||
| T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis | Q78074655 | ||
| Human and murine lymphocyte neurotrophin expression is confined to B cells | Q80535327 | ||
| Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients | Q81119751 | ||
| Natalizumab and PML | Q81273174 | ||
| Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis | Q81335035 | ||
| A role for B cell-activating factor of the TNF family in chemically induced autoimmunity | Q81375648 | ||
| Multiple sclerosis | Q81574168 | ||
| P433 | issue | 18 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 2343-2356 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | The potential role of B cell-targeted therapies in multiple sclerosis | |
| P478 | volume | 70 |
| Q43824626 | Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality |
| Q29010983 | Current and emerging therapies in multiple sclerosis: a systematic review |
| Q35276622 | Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis |
| Q38218692 | Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine |
| Q38133865 | Monoclonal antibodies in treatment of multiple sclerosis |
| Q48186044 | Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis |
| Q38924828 | Myeloid cells - targets of medication in multiple sclerosis. |
| Q92489483 | Pathogenic mechanisms of neurodegeneration based on the phenotypic expression of progressive forms of immune-mediated neurologic disease |
| Q40295389 | Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). |
| Q38690022 | Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. |
| Q91973492 | The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases |
Search more.